The Utah People's Post | Biogen Faces Delay in FDA Action Date - Analyst Blog NASDAQ In addition to Plegridy, Biogen has daclizumab in its MS pipeline. Biogen and partner AbbVie ( ABBV ) are conducting a two-year phase III study (DECIDE) on daclizumab with results due later this year. Biogen is also looking to expand Tysabri's label ... Biogen Idec Inc (NASDAQ:BIIB): A Biotech Pioneer With A Stellar Future |
